VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual tumor marker designed to provide artifact-free visibility across all major breast imaging ...
Despite such guidelines, though, the investigators said there is a lack of evidence-based or widely accepted consensus on ...
The main market opportunities in the global breast cancer imaging market include technological advancements in imaging modalities like tomosynthesis and CESM, increasing breast cancer incidence, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback